



Introduction: Our prior studies suggest that obesity and obesity-related factors alter the 
pharmacokinetics (PK) and pharmacodynamics (PD) of nanoparticles (NP), such as pegylated 
liposomal doxorubicin (Doxil®; PLD).  Specifically, obese patients will have higher circulating levels 
of hormones and chemokines which lead to higher mononuclear phagocyte system (MPS) function, 
higher NP clearance, and ultimately reduced tumor exposure and anti-cancer efficacy of NP 
compared to non-obese patients.  Thus we performed studies evaluating hormone and chemokine 
mediators in obese and non-obese patients with ovarian cancer and endometrial cancer. 
Methods: In obese and non-obese patients with ovarian and endometrial cancer, the 
concentration of estradiol, estrone, 5-dihydrotestosterone (DHT) and testosterone was measured in 
plasma samples using LC-MS/MS assays. In addition, CCL2 and CCL5 chemokines were 
measured using a multiplex immunochemistry assay.  
Results:  A univariate analysis for CCL5, CCL2, estrone, estradiol, testosterone and DHT 
revealed a significant odds ratio for the relationship between estradiol and body mass index (BMI) 
(OR 8.64, 95% CI 2.67-28.0, P<0.001).  A multivariate analysis was then performed to assess the 
effect of other factors, including BMI, age at diagnosis, stage and the concentration of other 
hormones and chemokines on estradiol concentration.  The multivariate analysis revealed that there 
was only a significant relationship between BMI and estradiol concentration.  
Conclusion:  A positive correlation was demonstrated between BMI and estradiol 
concentration.  Higher circulating levels of hormones in obese patients may explain reduced anti-
cancer efficacy of NP in obese patients compared to non-obese patients.  
  
Introduction: 
Nanotechnology offers a number of advantages over traditional drug 
delivery systems for the treatment of solid tumors1,2.  Advantages of NPs in solid 
tumor treatment include increased blood circulation time, enhanced delivery of 
entrapped drug to tumors, improved therapeutic time and a reduction in off target 
effects1,2.  The abnormal and distinctive blood and lymphatic vasculature allow for 
selective delivery and accumulation of nanoparticles (NP) at solid tumor sites via 
the enhanced permeability and retention effect (EPR)3.  Unfortunately, only a 
limited number of NPs have become clinically successful due to high interpatient 
and intra-patient variability in the pharmacokinetics (PK) and pharmacodynamics 
(PDs) of NPs4,5.   
 Various NP platforms exist, however liposomes, lipid vesicles formed by a 
lipid bilayer membrane surrounding an aqueous core, are the most common NP 
drug carriers approved by the FDA6.   One such carrier approved for use in humans 
is Doxil, also commonly known as PEGylated liposomal doxorubicin (PLD).  In a 
meta-analysis of interpatient variability in the PK of liposomal anticancer agents 
compared to small molecule (SM) formulations of the agent, the PK variability of 
liposomal drugs, measured as coefficient variance (CV%) of area under the 
concentration versus time curve (AUC), was significantly greater5.  This PK 
variability is significant as it has been associated with high variability in the efficacy 
and toxicity of NPs5,7,8.    
 Bone marrow-derived progenitors, blood monocytes and tissue 
macrophages comprise the mononuclear phagocyte system (MPS)9.  The MPS 
recognizes, internalizes and eventually clears NPs.  The immunological properties 
of NPs trigger the MPS10.  Identifying factors to predict the PK and PD of NPs, and 
to allow for selection of individualized dosing may further enhance tolerability and 
improve quality of life for patients with malignancy while preserving or improving 
efficacy11.  Our group previously reported associations between the PK variability 
of NPs and patient age, gender, body habitus, type of cancer and the function of 
monocytes in patients with cancer12-14.  Patients with a higher ratio of total body 
weight to ideal body weight had a higher clearance of PEGylated liposomal 
agents15,16.  In addition, the PK variability of NPs and other carrier-mediated agents 
(CMAs) is even greater in obese patients.  The factors affecting the PK of NPs and 
CMAs in obese patients are unclear, however we believe they may be attributed 
to the effects of serum hormones (e.g. testosterone and estrogens) on immune 
cell function17. This hypothesis is supported by a series of studies demonstrating 
that serum hormones, such as estrogens and testosterone, modulate immune 
system activity and macrophage phagocytic and chemotactic function. Of 
particular interest are the reports of various estrogens stimulating the phagocytic 
activity of the MPS in vitro18- 20.  
 Obesity has reached epidemic proportions in the United States. Based on 
body mass index (BMI), over 30% of adults are obese and 65% are overweight21-
24. Obesity has been linked to an increased risk of many cancers, including breast, 
colon, endometrial, and ovarian among others11. Currently, there are 
approximately 1.5 million new cancer cases associated with half a million cancer 
related deaths per year with nearly one in five due to obesity25-29.  
Obesity has been associated with increased risk and worse outcomes for 
both endometrial and ovarian cancer11,30.  We hypothesize that obesity and 
obesity-related factors alter the PK and PD of NPs, such as PLD.  Specifically, 
obese patients will have a higher distribution of NPs to fat and higher circulating 
levels of serum hormones and chemokines which lead to higher MPS function, 
higher NP clearance, and ultimately reduced tumor exposure and anti-cancer 
efficacy of NPs compared to non-obese patients.  These hormone and chemokine 
mediators of MPS function and NP PK and PD have not been extensively 
evaluated in patients with cancer and especially not as related to body habitus.  To 
test this hypothesis, we measured hormone and chemokine mediators in existing 
blood samples from obese and non-obese patients with ovarian and endometrial 
cancer enrolled on the UNC Health Registry/Cancer Survivorship Cohort (UNC 
CSC).  The UNC CSC is a registry of cancer survivors who consent to the use of 
their data and specimens for future research.  Specific aims of this study included 
profiling hormone and chemokine mediators of MPS function and NP PK/PD in 
obese and non-obese patients with ovarian and endometrial cancer.  
Methods: 
Patients with ovarian and endometrial cancer were selected based on the 
high incidence of obesity in these patients and the potential lower response to NP 
therapy in obese patients compared with non-obese patients11,30-35. Post-
menopausal Caucasian women were selected to maximize the ability to detect 
differences in hormone and chemokine exposures associated with obesity and not 
endocrine glands, and to remove potential effects of race. Patients were classified 
as being either obese or normal weight based on BMI.  According to the World 
Health Organization (WHO), a simple weight to height relationship called Body 
Mass Index (BMI) is used to classify body habitus in the adult population13,14.  The 
resulting value (kg/m2) is used to define underweight (BMI <18.5 kg/m2), normal 
weight (BMI: 18.5–24.9 kg/m2), overweight (BMI: 25-29.9 kg/m2), and obese (BMI 
>30 kg/m2). Following these guidelines, in our study obesity was defined as a BMI 
>30 kg/m2.  Normal weight was defined as a BMI between 18.5-24.9 kg/m2.  
Patients that would be classified as overweight based on BMI (25-30 kg/m2) were 
not included in this study.    
 Patient samples were obtained from the UNC CSC repository. The 
Biospecimen Processing Core Facility (BSP) functioned as the processing and 
biobanking core for the UNC CSC by processing blood specimens and repository 
management. The concentration of total estrogen, estrone, 5-dihydrotestosterone 
(DHT) and testosterone was measured in serum (500 uL) from each patient.  The 
concentration of CCL2 and CCL5 chemokines was measured in plasma (500 uL) 
from each patient27,28. Hormone and chemokines were measured in the UNC 
Cytokine and Biomarker Core Facility using an existing ELISA assays36.  Multiplex 
cytokine/chemokine assays (R&D Systems, Minneapolis, MN) were performed for 
quantification of CCL2 and CCL5 in plasma according to manufacturer’s protocol12. 
Statistical Analyses:  
Correlations between serum hormone and chemokine concentration and 
BMI were analyzed using univariate and multivariate logistic regression models. 
The concentration of hormones and chemokines were dichotomized at the median 
to convert them from a continuous to a discrete variable in order to use an odds 
ratio.  Concentrations below the median were considered “low concentration”.  
Concentrations above the median were considered “high concentration”.  
Results: 
A summary of the patient demographics for this study are included in Table 
1. The results of the univariate analysis for CCL5, CCL2, estrone, estradiol, 
testosterone and DHT are listed in Table 2.  In all patients, the odds ratio was 
significant for the relationship between estradiol and BMI (P=0.0003).  The odds 
of a high concentration of estradiol among obese patients was 8.64-times the odds 
of a high concentration of estradiol among non-obese patients (OR 8.64, 95% CI 
2.67-28.0).  A multivariate analysis was then performed in all patients to assess 
the effect of other factors, including BMI, age at diagnosis, stage and the 
concentration of other hormones and chemokines on estradiol concentration.  The 
multivariate analysis revealed a significant relationship between BMI and estradiol 
concentration (P=0.0023). These results can be found in Table 3. 
 The univariate analysis was repeated with obese and non-obese patients 
separated by cancer type.  In patients with ovarian cancer, the odds ratios were all 
non-significant.  In patients with endometrial cancer alone, the odds ratio for the 
relationship between estradiol and BMI increased indicating a stronger relationship 
than that between BMI and estradiol concentration in all patients (e.g. in patients 
with ovarian and endometrial) (OR 11.20, 95% CI 2.51-50.08, P=0.0016).  These 
results can be found in Table 4.  
 
Discussion: 
Obese patients are at an increased risk of developing cancer, having a 
recurrence of their cancer, and dying from their disease.  This makes finding an 
effective therapy in this population especially important.  Furthermore,  inter-patient 
variability in the PK and PD of NPs is greater in obese patients compared to other 
patients. Moreover, the efficacy of NPs of anticancer agents appears to be reduced 
in obese patients14,16,21,37. The decreased efficacy of NP-based therapies in obese 
patients is thought to happen by two mechanisms.  First, our group has 
demonstrated in mouse-models that NPs preferentially distribute to adipose tissue.  
A previous study evaluated the exposures of small molecule CKD-602, a 
camptothecin analogue, with a PEGylated liposomal formulation of CKD-602 (S-
CKD-602) in muscle and fat tissue.  There was a 3.8-fold higher ratio of CKD-602 
sum total exposure in fat to muscle after administration of S-CKD-602 as compared 
with non-liposomal CKD-602 highlights14.  The greater exposure of NP in fat versus 
muscle reflects an increased distribution of NPs to adipose tissue which results in 
an increased volume of distribution, reduced accumulation in target tumor tissue, 
and ultimately decreased efficacy of the drug.   However, when comparing PK 
differences in obese and non-obese patients we have observed nearly ten-fold 
differences in plasma exposures indicating a second more dominant mechanism 
associated with lower plasma exposure of NPs14.  The second mechanism thought 
to be responsible for reduced plasma exposure of NPs in obese patients is related 
to higher blood clearance of NPs in these patients.  Previous studies have 
demonstrated that the mediators and function of MPS on NP PK and PD appear 
to be higher in obese patients compared to other patients13,38.  The current study 
sought to test the hypothesis that obese patients with cancer have elevated levels 
of hormones and chemokines.  To be clinically relevant these studies were 
performed in patients with ovarian and endometrial cancer which have a high 
incidence of obesity and in which PLD has been used as treatment. 
The results of this study evaluating hormone and chemokine exposures in 
obese and non-obese patients with ovarian and endometrial cancer demonstrated 
a significant odds ratio for the relationship between estradiol and BMI (OR 8.64, 
95% CI 2.67-28.0, P=0.0003) in all patients.  Moreover, there was a stronger 
relationship between estradiol and BMI in patients with endometrial cancer (OR 
11.20, 95% CI 2.51-50.08, P=0.0016). Despite existing data demonstrating the 
ability of adipocytes to synthesize hormones and obesity as a chemokine mediated 
inflammatory condition, the relationship between obesity and plasma hormone and 
chemokine concentrations remains unclear39.  A significant odds ratio for the 
relationship between BMI and concentration of estradiol supports our hypothesis 
that obese patients have higher circulating levels of hormones.  However, 
according to our hypothesis, we would have also expected significant relationships 
between the other hormones tested and BMI.  Given that estrone and estradiol are 
readily interconverted by 17β-Hydroxysteroid dehydrogenase (17β-HSD) and that 
testosterone can be converted by CYP19 into estradiol, a significant relationship 
between the concentration of estrone and BMI and the concentration of 
testosterone and BMI may be absent because of enzyme kinetics in adipose tissue 
that favor the conversion of these hormones to estradiol.  A similar explanation is 
possible for the absence of a significant relationship between DHT and BMI.  In 
adipocytes testosterone can be converted by CYP19 into estradiol or by 5a-
reductase (SR5A1) into DHT39.  If the testosterone is being shunted to the estradiol 
pathway, there may not be sufficient reserves for the generation of DHT thus 
clouding the relationship between DHT and BMI. 
 It is of note that the odds ratio for the concentration of estradiol and BMI 
was not significant across patients with ovarian cancer and endometrial cancer 
when analyzed separately.  The odds ratio for the relationship between estradiol 
and BMI remained significant and increased for endometrial cancer, indicating a 
stronger relationship between the variables when the patients with ovarian cancer 
were not included.  The odds ratio for the relationship between estradiol and BMI 
was not significant when patients with ovarian cancer were assessed alone.  This 
may be due to a significant difference in the BMI in the obese patients with 
endometrial cancer compared with ovarian cancer.  The mean ± SD BMI for the 
obese patients with endometrial cancer and ovarian cancer were 46.26 ± 4.41 and 
32.78 ± 3.48, respectively. Morbid obesity is defined as a BMI greater than 40.  All 
obese patients with endometrial cancer enrolled in the study were considered 
morbidly obese with BMIs ranging from 42.2 to 61.2.  The BMIs for obese patients 
with ovarian cancer ranged from 30.2 to 40.7 with only one of the patients with 
ovarian cancer having a BMI >40.  The differences in the magnitude of obesity 
offer a possible explanation for the lack of continuity of the significant relationship 
between BMI and estradiol concentration across the two cancer types.  It may be 
that the relationship between hormone concentration and BMI does not become 
significant until patients are morbidly obese. Additional studies are need to 
evaluate these factors. 
 PLD is approved for the treatment of ovarian cancer but not endometrial 
cancer.  Patients with ovarian cancer have a greater response to PLD than patients 
with endometrial cancer40,41.  The results of this study suggest that the decreased 
efficacy of PLD in patients with endometrial cancer, especially as compared to its 
efficacy in patients with ovarian cancer, may be due to an increased incidence of 
morbid obesity, higher estradiol exposures which leads to higher MPS function and 
lower exposures of PLD.  This hypothesis is consistent with the results of the study 
presented in this publication. The study reported significantly higher BMI and a 
greater association between BMI and estradiol exposures in patients with 
endometrial cancer compared with ovarian cancer.  This study suggests that 
hormone concentrations and MPS function in blood are potentially useful for 
individualizing the dose of PLD and other NPs in obese patients with cancer.  
Moreover, these results suggest that obese patients with ovarian cancer and 
especially endometrial cancer may require a higher dose of PLD to achieve similar 
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Figures and Tables: 
Table 1: Patient demographics, hormone and chemokine concentrations 
Demographic or 
Result 










  Mean ± SD 
(Range) 
  
BMI (kg/m2) Obese Wt 41.5 ± 7.2 46.2 ± 4.6 34.3 ± 3.64 
 Normal Wt 22.7 ± 1.68 22.5 ± 1.96 23.1 ± 0.67 
     
TBW (kg) Obese Wt 110.21 ± 22.18 122.7 ± 17.77 90.98 ± 12.3 
 Normal Wt 59.25 ± 6.73 58.1 ± 7.42 61.8 ± 3.88 
     
BSA (m2) Obese Wt 2.1 ± 0.21 2.2 ± 0.18 1.96 ± 0.16 
 Normal Wt 1.62 ± 0.12 1.6 ± 0.13 1.67 ± 0.07 
     
Estradiol (pg/mL) Obese Wt 110.03 ± 73.2 126.6 ± 81.97 84.6 ± 50.03 
 Normal Wt 61.7 ± 50.58 59.8 ± 47.67 65.9 ± 56.01 
     
Estrone (pg/mL) Obese Wt 73.1 ± 28.1 75.9 ± 30.4 68.6 ± 24.55 
 Normal Wt 62.1 ± 20.7 59.5 ± 19.25 68.1 ± 22.52 
     
Testosterone (pg/mL) Obese Wt 4.75 ± 16.99 7.05 ± 21.71 1.20 ± 0.74 
 Normal Wt 1.26 ± 1.29 1.34 ± 1.44 1.07 ± 0.89 
     
5-DHT (pg/mL) Obese Wt 205.7 ± 141.2 237.6 ± 164.7 156.7 ± 76.88 
 Normal Wt 147.01 ± 86.2 151.8 ± 92.26 136.3 ± 70.63 
     
CCL2 (pg/mL) Obese Wt 178.98 ± 84.4 38613.2 ± 5653.7 217.5 ± 113.5 
 Normal Wt 174.14 ± 86.2 140.7 ± 69.7  248.4 ± 218.97 
     
CCL5 (pg/mL) Obese Wt 16313.8 ± 14931.3 13867.8 ± 14137.6 19770.4 ± 22206.6 
 Normal Wt 19703.3 ± 25396.7 19673.2 ± 27255.8 20076.9 ± 15897.7 
  
Table 2. Univariate Analysis: Odds of high concentration of 
hormone/chemokine among obese vs. normal ovarian and endometrial 
patients enrolled on the UNC Cancer Survivorship Cohort 
Predictor = 
Obesity Odds Ratio 
95% Confidence 
Interval P-value 
CCL5 1.07 0.39-2.98 0.8947 
CCL2 2.48 0.87-7.12 0.0901 
Estrone 1.85 0.66-5.21 0.2422 
Estradiol 8.64 2.67-28.0 0.0003 
Testosterone 2.14 0.76-6.06 0.1521 
DHT 1.85 0.66-5.21 0.2422 
 
  
Table 3. Multivariate Analysis for Estradiol: odds of high concentration of 
estradiol among obese patients, adjusted for site, stage, age at diagnosis, and 
other hormone/chemokine concentrations. *Reference group: Stage 1-2. 
 Odds Ratio 
95% Confidence 
Interval P-Value 
BMI 8.33 2.05-33.85 0.0030 
Age at diagnosis 0.58 0.15-2.29 0.4356 
Stage 3-4* 2.53 0.21-30.32 0.4629 
Stage Unknown* 0.69 0.15-3.17 0.6316 
CCL5 0.65 0.15-2.71 0.5503 
CCL2 0.90 0.18-4.50 0.8933 
Estrone 0.44 0.07-2.85 0.3896 
Testosterone 2.78 0.24-35.51 0.4156 





Table 4. Univariate Analysis: Odds of high hormone/chemokine concentration among 
obese vs. normal patients enrolled on Cancer Survivorship Cohort by cancer type 
Mediator Endometrial Cancer Ovarian Cancer 
Odds 
Ratio 
95% CI P-Value Odds 
Ratio 
95% CI P-Value 
CCL5 0.89 0.25-3.16 0.8554 1.40 0.23-8.46 0.7140 
CCL2 1.70 0.45-6.36 0.4325 5.63 0.75-42.36 0.0936 
Estrone 3.25 0.87-12.13 0.0796 0.714 0.12-4.32 0.7140 
Estradiol 11.20 2.51-50.08 0.0016 5.33 0.78-36.33 0.0873 
Testosterone 3.25 0.87-12.13 0.0796 1.14 0.18-7.23 0.8876 
DHT 2.57 0.71-9.36 0.1519 1.04 0.18-6.12 0.9640 
 
